{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:46:02Z","timestamp":1780357562384,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-025-01977-1","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T06:24:34Z","timestamp":1741760674000},"page":"674-682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stereotactic body radiotherapy combined with immunotherapy or targeted therapy: a screenshot from Italy on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO)"],"prefix":"10.1007","volume":"130","author":[{"given":"Giulia","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marvaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-3149","authenticated-orcid":false,"given":"Maria Giulia","family":"Vincini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Badellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Montesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pontoriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"1977_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148:157\u2013166","journal-title":"Radiother Oncol"},{"key":"1977_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","volume":"114","author":"S Harrow","year":"2022","unstructured":"Harrow S et al (2022) Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiat Oncol Biol Phys 114:611\u2013616","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1977_CR3","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.3390\/cancers13225773","volume":"13","author":"DL Billing","year":"2021","unstructured":"Billing DL, Rimner A (2021) Results of radiation therapy as local ablative therapy for oligometastatic non-small cell lung cancer. Cancers (Basel) 13:5773","journal-title":"Cancers (Basel)"},{"key":"1977_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","volume":"13","author":"H Gharwan","year":"2016","unstructured":"Gharwan H, Groninger H (2016) Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 13:209\u2013227","journal-title":"Nat Rev Clin Oncol"},{"key":"1977_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2018.11.009","volume":"133","author":"L Belgioia","year":"2019","unstructured":"Belgioia L et al (2019) Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review. Crit Rev Oncol Hematol 133:163\u2013170","journal-title":"Crit Rev Oncol Hematol"},{"key":"1977_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1021\/cr800504x","volume":"109","author":"PJ Tofilon","year":"2009","unstructured":"Tofilon PJ, Camphausen K (2009) Molecular targets for tumor radiosensitization. Chem Rev 109:2974\u20132988","journal-title":"Chem Rev"},{"key":"1977_CR7","doi-asserted-by":"crossref","unstructured":"ESTRO 2024\u2014Abstract Book. https:\/\/user-swndwmf.cld.bz\/ESTRO-2024-Abstract-Book\/1848\/.","DOI":"10.22159\/ijap.2025v17i1.53183"},{"key":"1977_CR8","first-page":"93","volume":"33","author":"ESM van Aken","year":"2022","unstructured":"van Aken ESM et al (2022) Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: dutch survey on current practice, knowledge and challenges. Clin Transl Radiat Oncol 33:93\u201398","journal-title":"Clin Transl Radiat Oncol"},{"key":"1977_CR9","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze SGC et al (2023) Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol 24:e121\u2013e132","journal-title":"Lancet Oncol"},{"key":"1977_CR10","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S1470-2045(24)00023-8","volume":"25","author":"G Marvaso","year":"2024","unstructured":"Marvaso G et al (2024) Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a european society for radiotherapy and oncology study endorsed by the european association of urology. Lancet Oncol 25:e193\u2013e204","journal-title":"Lancet Oncol"},{"key":"1977_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bju.15284","volume":"127","author":"SGC Kroeze","year":"2021","unstructured":"Kroeze SGC et al (2021) Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int 127:703\u2013711","journal-title":"BJU Int"},{"key":"1977_CR12","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/j.clgc.2019.12.009","volume":"18","author":"J Higa","year":"2020","unstructured":"Higa J et al (2020) Real world experience with pembrolizumab in recurrent or advanced prostate cancer. Clin Genitourin Cancer 18:e397\u2013e401","journal-title":"Clin Genitourin Cancer"},{"key":"1977_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","volume":"88","author":"GN Gan","year":"2014","unstructured":"Gan GN et al (2014) Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88:892\u2013898","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1977_CR14","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","volume":"7","author":"AJ Weickhardt","year":"2012","unstructured":"Weickhardt AJ et al (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7:1807\u20131814","journal-title":"J Thorac Oncol"},{"key":"1977_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.rpor.2015.07.005","volume":"21","author":"D Stefan","year":"2016","unstructured":"Stefan D et al (2016) Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: a case report. Rep Pract Oncol Radiother 21:76\u201380","journal-title":"Rep Pract Oncol Radiother"},{"key":"1977_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.lungcan.2020.12.029","volume":"152","author":"M Blake-Cerda","year":"2021","unstructured":"Blake-Cerda M et al (2021) Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: a prospective phase 2 study. Lung Cancer 152:119\u2013126","journal-title":"Lung Cancer"},{"key":"1977_CR17","first-page":"5947","volume":"14","author":"R Bruno","year":"2017","unstructured":"Bruno R et al (2017) Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: a case report. Oncol Lett 14:5947\u20135951","journal-title":"Oncol Lett"},{"key":"1977_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2020.02.002","volume":"142","author":"OSH Chan","year":"2020","unstructured":"Chan OSH et al (2020) ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. Lung Cancer 142:41\u201346","journal-title":"Lung Cancer"},{"key":"1977_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.clon.2017.04.035","volume":"29","author":"OSH Chan","year":"2017","unstructured":"Chan OSH et al (2017) The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis. Clin Oncol (R Coll Radiol) 29:568\u2013575","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1977_CR20","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","volume":"32","author":"P Iyengar","year":"2014","unstructured":"Iyengar P et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32:3824\u20133830","journal-title":"J Clin Oncol"},{"key":"1977_CR21","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2147\/OTT.S300267","volume":"14","author":"K-H Hsu","year":"2021","unstructured":"Hsu K-H et al (2021) Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment na\u00efve advanced EGFR-mutant lung adenocarcinoma patients. Onco Targets Ther 14:2139\u20132148","journal-title":"Onco Targets Ther"},{"key":"1977_CR22","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.3390\/cancers13194780","volume":"13","author":"SGC Kroeze","year":"2021","unstructured":"Kroeze SGC et al (2021) Continued versus interrupted targeted therapy during metastasis-directed stereotactic radiotherapy: a retrospective multi-center safety and efficacy analysis. Cancers (Basel) 13:4780","journal-title":"Cancers (Basel)"},{"key":"1977_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13014-020-01730-0","volume":"16","author":"SGC Kroeze","year":"2021","unstructured":"Kroeze SGC et al (2021) Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the \u2018TOaSTT\u2019 database. Radiat Oncol 16:4","journal-title":"Radiat Oncol"},{"key":"1977_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijrobp.2015.02.016","volume":"92","author":"EL Pollom","year":"2015","unstructured":"Pollom EL et al (2015) Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 92:568\u2013576","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1977_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jamaoncol.2019.0205","volume":"5","author":"C Wang","year":"2019","unstructured":"Wang C et al (2019) Analysis of toxic effects with antiangiogenic agents plus stereotactic body radiation in ultracentral lung tumors. JAMA Oncol 5:737\u2013739","journal-title":"JAMA Oncol"},{"key":"1977_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ijrobp.2016.01.038","volume":"95","author":"CJ Anker","year":"2016","unstructured":"Anker CJ et al (2016) Avoiding severe toxicity from combined braf inhibitor and radiation treatment: consensus guidelines from the eastern cooperative oncology group (ECOG). Int J Radiat Oncol Biol Phys 95:632\u2013646","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1977_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","volume":"53","author":"SGC Kroeze","year":"2017","unstructured":"Kroeze SGC et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25\u201337","journal-title":"Cancer Treat Rev"},{"key":"1977_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","volume":"87","author":"BM Barney","year":"2013","unstructured":"Barney BM et al (2013) Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 87:73\u201380","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1977_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/1754-9485.12489","volume":"60","author":"NA Haji MohdYasin","year":"2016","unstructured":"Haji MohdYasin NA, Gray AR, Bevin TH, Kelly LE, Molteno AC (2016) Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: the\u00a0dunedin hospital experience. J Med Imaging Radiat Oncol 60:756\u2013763","journal-title":"J Med Imaging Radiat Oncol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-01977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-01977-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-01977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:05:44Z","timestamp":1748228744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-01977-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["1977"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-01977-1","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Division of Radiation Oncology of IEO received research funding from AIRC (Italian Association for Cancer Research), Fondazione IEO-CCM (Istituto Europeo di Oncologia-Centro Cardiologico Monzino), ACCURAY, IBA (Ion Beam applications). BAJF received speaker\u2019s fees from BAYER, ACCURAY, ASTELLAS, IBA, IPSEN, ASTRA ZENECA, TECNOLOGIE AVANZATE, RECORDATI, NOVARTIS; BAJF participated to Advisory Board of ACCURAY, BAYER, SEAGEN, all outside the current project. These companies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and\/or in the decision to publish the results. SB received speaker\u2019s fees from ELEKTA, ACCURAY, ASTRAZENECA. The remaining authors declare no conflicts of interest that are relevant to the content of this article. PB received speaker\u2019s fees from ASTRAZENECA, ROCHE, TAKEDA, AMGEN.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}}]}}